M&A Corner
Medidata acquires SHYFT analytics for $195M, adds analytics to life sciences suite25 Jun 2018
Medidata said it will acquire SHYFT for $195 million in a deal designed to expand its reach in life sciences... Continue Reading
|
Esco Group to acquire AT Medical UAB, an Esco Ventures portfolio company, to accelerate development of the Esco life sciences ecosystem and delivery of innovative fertility technologies25 Jun 2018
Esco Group announced today that it has reached an agreement to acquire the remaining shares in AT Medical UAB, an... Continue Reading
|
Bayer wins EU approval for $62.5 billion Monsanto buy25 Jun 2018
German conglomerate Bayer won EU antitrust approval on Wednesday for its $62.5 billion buy of U.S. peer Monsanto, the latest... Continue Reading
|
Sanofi’s for-sale generics unit is too pricey, or so says dropout bidder13 Jun 2018
As Sanofi presses ahead with the sale of its European generics business, a private equity firm has bowed out, saying... Continue Reading
|
Advent, near deal to buy Sanofi’s Zentiva, lays out big goals for generics business13 Jun 2018
The sources were right: Only one day after numerous media reports stated Sanofi was nearing a deal with Advent International... Continue Reading
|
May round-up of pharmaceutical & biotech M&A activity13 Jun 2018
This was a month that will likely be remembered as when Takeda and Shire shook hands on a $62 billion... Continue Reading
|
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook13 Jun 2018
Barclays analysts did a roll call this week, checking in on each of their stocks and adjusting their ratings and... Continue Reading
|
Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst13 Jun 2018
The $62 billion Takeda-Shire deal surprised everyone—and worries some—as Takeda is borrowing an enormous $31 billion to help pay for... Continue Reading
|
Biogen poaches Pfizer dealmaker Dan Karp for stepped-up M&A push13 Jun 2018
Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On... Continue Reading
|
Bye-bye, solo Express Scripts: What does the Cigna buyout mean for pharma?13 Jun 2018
Healthcare consolidation took another major step Thursday with Cigna’s move to scoop up the last large independent pharmacy benefits manager... Continue Reading
|